Skip to main content
NCD 310.1 · version 3

NCD 310.1: Routine Costs in Clinical Trials

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database NCDs: API snapshot September 27, 2026 (effective September 20, 2026). Next CMS release: weekly, every Thursday.

Medicare Coverage Database NCDs: the loaded version is API snapshot September 27, 2026, and the CMS schedule called for a newer one from October 1, 2026. Verify figures against the current CMS publication until this reference is rebuilt; pages built on it are withdrawn from search indexing until then.

Key facts for NCD 310.1

Benefit category
Ambulance Services, Ambulatory Surgical Center Facility Services, Antigens, Artificial Legs, Arms, and Eyes, Audiology Services, Blood Clotting Factors for Hemophilia Patients, Bone Mass Measurement, Certified Nurse-Midwife Services, Certified Registered Nurse Anesthetist Services, Chiropractor Services, Clinical Nurse Specialist Services, Clinical Social Worker Services, Colorectal Cancer Screening Tests, Comprehensive Outpatient Rehabilitation Facility (CORF) Services, Critical Access Hospital Services, Dentist Services, Diabetes Outpatient Self-Management Training, Diagnostic Laboratory Tests, Diagnostic Services in Outpatient Hospital, Diagnostic Tests (other), Diagnostic X-Ray Tests, Drugs and Biologicals, Durable Medical Equipment, Erythropoietin for Dialysis Patients, Extended Care Services, Eyeglasses After Cataract Surgery, Federally Qualified Health Center Services, Hepatitis B Vaccine and Administration, Home Dialysis Supplies and Equipment, Home Health Services, Hospice Care, Immunosuppressive Drugs, Incident to a physician's professional Service, Influenza Vaccine and Administration, Inpatient Hospital Services, Inpatient Psychiatric Hospital Services, Institutional Dialysis Services and Supplies, Leg, Arm, Back, and Neck Braces (orthotics), Medical Nutrition Therapy Services, Nurse Practitioner Services, Optometrist Services, Oral Anticancer Drugs, Oral Antiemetic Drugs, Orthotics and Prosthetics, Osteoporosis Drug, Outpatient Hospital Services Incident to a Physician's Service, Outpatient Occupational Therapy Services, Outpatient Physical Therapy Services, Outpatient Speech Language Pathology Services, Partial Hospitalization Services, Physician Assistant Services, Physicians' Services, Pneumococcal Vaccine and Administration, Podiatrist Services, Post-Hospital Extended Care Services, Post-Institutional Home Health Services, Prostate Cancer Screening Tests, Prosthetic Devices, Qualified Psychologist Services, Religious NonMedical Health Care Institution, Rural Health Clinic Services, Screening for Glaucoma, Screening Mammography, Screening Pap Smear, Screening Pelvic Exam, Self-Care Home Dialysis Support Services, Shoes for Patients with Diabetes, Skilled Nursing Facility, Splints, Casts, Other Devices Used for Reduction of Fractures and Dislocations, Surgical Dressings, Transplantation Services for ESRD-Entitled Beneficiaries, X-ray, Radium, and Radioactive Isotope Therapy
Effective date
05/27/2024
Implemented 05/27/2024
Transmittal
Transmittal 12590
Versions published
3
Manual section
310
Clinical Trials, NCD Manual (Pub. 100-03) chapter 1 part 4

TL;DR

NCD 310.1 sets Medicare's national policy for routine costs in clinical trials under the benefit category "Ambulance Services, Ambulatory Surgical Center Facility Services, Antigens, Artificial Legs, Arms, and Eyes, Audiology Services, Blood Clotting Factors for Hemophilia Patients, Bone Mass Measurement, Certified Nurse-Midwife Services, Certified Registered Nurse Anesthetist Services, Chiropractor Services, Clinical Nurse Specialist Services, Clinical Social Worker Services, Colorectal Cancer Screening Tests, Comprehensive Outpatient Rehabilitation Facility (CORF) Services, Critical Access Hospital Services, Dentist Services, Diabetes Outpatient Self-Management Training, Diagnostic Laboratory Tests, Diagnostic Services in Outpatient Hospital, Diagnostic Tests (other), Diagnostic X-Ray Tests, Drugs and Biologicals, Durable Medical Equipment, Erythropoietin for Dialysis Patients, Extended Care Services, Eyeglasses After Cataract Surgery, Federally Qualified Health Center Services, Hepatitis B Vaccine and Administration, Home Dialysis Supplies and Equipment, Home Health Services, Hospice Care, Immunosuppressive Drugs, Incident to a physician's professional Service, Influenza Vaccine and Administration, Inpatient Hospital Services, Inpatient Psychiatric Hospital Services, Institutional Dialysis Services and Supplies, Leg, Arm, Back, and Neck Braces (orthotics), Medical Nutrition Therapy Services, Nurse Practitioner Services, Optometrist Services, Oral Anticancer Drugs, Oral Antiemetic Drugs, Orthotics and Prosthetics, Osteoporosis Drug, Outpatient Hospital Services Incident to a Physician's Service, Outpatient Occupational Therapy Services, Outpatient Physical Therapy Services, Outpatient Speech Language Pathology Services, Partial Hospitalization Services, Physician Assistant Services, Physicians' Services, Pneumococcal Vaccine and Administration, Podiatrist Services, Post-Hospital Extended Care Services, Post-Institutional Home Health Services, Prostate Cancer Screening Tests, Prosthetic Devices, Qualified Psychologist Services, Religious NonMedical Health Care Institution, Rural Health Clinic Services, Screening for Glaucoma, Screening Mammography, Screening Pap Smear, Screening Pelvic Exam, Self-Care Home Dialysis Support Services, Shoes for Patients with Diabetes, Skilled Nursing Facility, Splints, Casts, Other Devices Used for Reduction of Fractures and Dislocations, Surgical Dressings, Transplantation Services for ESRD-Entitled Beneficiaries, X-ray, Radium, and Radioactive Isotope Therapy", effective 05/27/2024 and implemented 05/27/2024. Effective for items and services furnished on or after July 9, 2007, Medicare covers the routine costs of qualifying clinical trials, as such costs are defined below, as well as reasonable and necessary items and services used to diagnose and treat… It has been revised 2 times since publication and binds every Medicare Administrative Contractor nationally.

Indications and limitations of coverage

Effective for items and services furnished on or after July 9, 2007, Medicare covers the routine costs of qualifying clinical trials, as such costs are defined below, as well as reasonable and necessary items and services used to diagnose and treat complications arising from participation in all clinical trials. All other Medicare rules apply.

Routine costs of a clinical trial include all items and services that are otherwise generally available to Medicare beneficiaries (i.e., there exists a benefit category, it is not statutorily excluded, and there is not a national non-coverage decision) that are provided in either the experimental or the control arms of a clinical trial except:

• The investigational item or service, itself unless otherwise covered outside of the clinical trial;

• Items and services provided solely to satisfy data collection and analysis needs and that are not used in the direct clinical management of the patient (e.g., monthly CT scans for a condition usually requiring only a single scan); and

• Items and services customarily provided by the research sponsors free-of-charge for any enrollee in the trial.

Routine costs in clinical trials include:

• Items or services that are typically provided absent a clinical trial (e.g., conventional care);

• Items or services required solely for the provision of the investigational item or service (e.g., administration of a non-covered chemotherapeutic agent), the clinically appropriate monitoring of the effects of the item or service, or the prevention of complications; and

• Items or services needed for reasonable and necessary care arising from the provision of an

investigational item or service—in particular, for the diagnosis or treatment of complications.

This policy does not withdraw Medicare coverage for items and services that may be covered according to local coverage determination (LCDs) or the regulations on category B investigational device exemptions found in 42 CFR 405.201-405.215, 411.15, and 411.406. For information about LCDs, refer to https://www.cms.gov/medicare-coverage-database/search.aspx a searchable database of Medicare Administrative Contractor local policies.

For non-covered items and services, including items and services for which Medicare payment is statutorily prohibited, Medicare only covers the treatment of complications arising from the delivery of the noncovered item or service and unrelated reasonable and necessary care. However, if the item or service is not covered by virtue of a national non-coverage policy in Pub. 100-03, National Coverage Determination (NCD) Manual, and is the focus of a qualifying clinical trial, the routine costs of the clinical trial (as defined above) will be covered by Medicare but the non-covered item or service, itself, will not.

A. Requirements for Medicare Coverage of Routine Costs

Any clinical trial receiving Medicare coverage of routine costs must meet the following three requirements:

• The subject or purpose of the trial must be the evaluation of an item or service that falls within a Medicare benefit category (e.g., physicians' service, durable medical equipment, diagnostic test) and is not statutorily excluded from coverage (e.g., cosmetic surgery, hearing aids).

• The trial must not be designed exclusively to test toxicity or disease pathophysiology. It must have therapeutic intent.

• Trials of therapeutic interventions must enroll patients with diagnosed disease rather than healthy volunteers. Trials of diagnostic interventions may enroll healthy patients in order to have a proper control group.

The three requirements above are insufficient by themselves to qualify a clinical trial for Medicare coverage of routine costs. Clinical trials also should have the following desirable characteristics; however, some trials, as described below, are presumed to meet these characteristics and are automatically qualified to receive Medicare coverage:

• The principal purpose of the trial is to test whether the intervention potentially improves the participants' health outcomes;

• The trial is well-supported by available scientific and medical information or it is intended to clarify or establish the health outcomes of interventions already in common clinical use;

• The trial does not unjustifiably duplicate existing studies;

• The trial design is appropriate to answer the research question being asked in the trial;

• The trial is sponsored by a credible organization or individual capable of executing the proposed trial successfully;

• The trial is in compliance with Federal regulations relating to the protection of human subjects; and

• All aspects of the trial are conducted according to the appropriate standards of scientific integrity.

B. Qualification Process for Clinical Trials

Using the authority found in §1142 of the Social Security Act (the Act) (cross-referenced in §1862(a)(1)(E) of the Act), the Agency for Healthcare Research and Quality (AHRQ) will convene a multi-agency Federal panel (the "panel") composed of representatives of the Department of Health and Human Services research agencies (National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), AHRQ, and the Office of Human Research Protection), and the research arms of the Department of Defense (DOD) and the Department of Veterans Affairs (VA) to develop qualifying criteria that will indicate a strong probability that a trial exhibits the desirable characteristics listed above. These criteria will be easily verifiable, and where possible, dichotomous. Trials that meet these qualifying criteria will receive Medicare coverage of their associated routine costs. This panel is not reviewing or approving individual trials. The multi-agency panel will meet periodically to review and evaluate the program and recommend any necessary refinements to the Centers for Medicare & Medicaid Services (CMS).

Clinical trials that meet the qualifying criteria will receive Medicare coverage of routine costs after the trial's lead principal investigator certifies that the trial meets the criteria. This process will require the principal investigator to enroll the trial in a Medicare clinical trials registry, currently under development.

Some clinical trials are automatically qualified to receive Medicare coverage of their routine costs because they have been deemed by AHRQ, in consultation with the other agencies represented on the multi-agency panel to be highly likely to have the above-listed seven desirable characteristics of clinical trials. The principal investigators of these automatically qualified trials do not need to certify that the trials meet the qualifying criteria, but must enroll the trials in the Medicare clinical trials registry for administrative purposes, once the registry is established.

Effective September 19, 2000, clinical trials that are deemed to be automatically qualified are:

• Trials funded by NIH, CDC, AHRQ, CMS, DOD, and VA;

• Trials supported by centers or cooperative groups that are funded by the NIH, CDC, AHRQ, CMS, DOD, and VA;

• Trials conducted under an investigational new drug application (IND) reviewed by the FDA; and

• Drug trials that are exempt from having an IND under 21 CFR 312.2(b)(1) will be deemed automatically qualified until the qualifying criteria are developed and the certification process is in place. At that time the principal investigators of these trials must certify that the trials meet the qualifying criteria in order to maintain Medicare coverage of routine costs. This certification process will only affect the future status of the trial and will not be used to retroactively change the earlier deemed status.

The CMS, through the NCD process, through an individualized assessment of benefits, risks, and research potential, may determine that certain items and services for which there is some evidence of significant medical benefit, but for which there is insufficient evidence to support a “reasonable and necessary” determination, are only reasonable and necessary when provided in a clinical trial that meets the requirements defined in that NCD.

Medicare will cover the routine costs of qualifying trials that either have been deemed to be automatically qualified, have certified that they meet the qualifying criteria, or are required through the NCD process, unless CMS's Chief Clinical Officer subsequently finds that a clinical trial does not meet the qualifying criteria or jeopardizes the safety or welfare of Medicare beneficiaries.

Should CMS find that a trial's principal investigator misrepresented that the trial met the necessary qualifying criteria in order to gain Medicare coverage of routine costs, Medicare coverage of the routine costs would be denied under §1862(a)(1)(E) of the Act. In the case of such a denial, the Medicare beneficiaries enrolled in the trial would not be held liable (i.e., would be held harmless from collection) for the costs consistent with the provisions of §§1879, 1842(l), or 1834(j)(4) of the Act, as applicable. Where appropriate, the billing providers would be held liable for the costs and fraud investigations of the billing providers and the trial's principal investigator may be pursued.

Medicare regulations require Medicare+Choice (M+C) organizations to follow CMS NCDs. This NCD raises special issues that require some modification of most M+C organizations' rules governing provision of items and services in and out of network. The items and services covered under this NCD are inextricably linked to the clinical trials with which they are associated and cannot be covered outside of the context of those clinical trials. M+C organizations therefore must cover these services regardless of whether they are available through in-network providers. M+C organizations may have reporting requirements when enrollees participate in clinical trials, in order to track and coordinate their members' care, but cannot require prior authorization or approval.

(This NCD last reviewed July 2007.)

Text reproduced from the CMS Medicare Coverage Database record for NCD 310.1 version 3. View the original on cms.gov.

Local policies that build on this NCD

8 active Local Coverage Determinations cite NCD 310.1 among their related national policies. An LCD may not conflict with the national determination; read it for the contractor's documentation and coding detail in that jurisdiction.

How MACs bill NCD 310.1

A National Coverage Determination states the policy; the Medicare Administrative Contractors publish the articles that turn it into claim edits. 5 current articles in the Medicare Coverage Database name NCD 310.1, 2 of them with a covered ICD-10-CM list, from 4 contractors. The lists can differ by contractor even though the NCD is national, because each MAC codes the policy for its own claims system; check the article of the contractor that processes the claim.

A59175: Billing and Coding: Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin

Billing and Coding, effective 2026-03-05 · Noridian Healthcare Solutions, LLC (01111, 01112, 01182, 01211, 01212, 01311, 01312, 01911, 02101, 02102, 02201, 02202, 02301, 02302, 02401, 02402, 03101, 03102, 03201, 03202, 03301, 03302, 03401, 03402, 03501, 03502, 03601, 03602) · CMS record

352 covered ICD-10-CM codes; 1 procedure code: 38240. Local policy: L39396 Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin. Check a diagnosis for 38240.

First covered codes: C81.00 Nodular lymphocyte predominant Hodgkin lymphoma, unspecified site; C81.01 Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of head, face, and neck; C81.02 Nodular lymphocyte predominant Hodgkin lymphoma, intrathoracic lymph nodes; C81.03 Nodular lymphocyte predominant Hodgkin lymphoma, intra-abdominal lymph nodes; C81.04 Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of axilla and upper limb; C81.05 Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of inguinal region and lower limb; …

A59311: Billing and Coding: Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin and Non-Hodgkin Lymphoma with B-cell or T-cell Origin

Billing and Coding, effective 2026-04-01 · Wellpoint Federal (06101, 06102, 06201, 06202, 06301, 06302, 13101, 13102, 13201, 13202, 13282, 13292, 14111, 14112, 14211, 14212, 14311, 14312, 14411, 14412, 14511, 14512) · CMS record

380 covered ICD-10-CM codes; 1 procedure code: 38240. Local policy: L39513 Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin and Non-Hodgkin Lymphoma with B-cell or T-cell Origin. Check a diagnosis for 38240.

First covered codes: C81.00 Nodular lymphocyte predominant Hodgkin lymphoma, unspecified site; C81.01 Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of head, face, and neck; C81.02 Nodular lymphocyte predominant Hodgkin lymphoma, intrathoracic lymph nodes; C81.03 Nodular lymphocyte predominant Hodgkin lymphoma, intra-abdominal lymph nodes; C81.04 Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of axilla and upper limb; C81.05 Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of inguinal region and lower limb; …

A52430: Clinical Trials – Medical Policy Article

Article, effective 2025-12-04 · CGS Administrators, LLC (15101, 15102, 15201, 15202) · CMS record

No covered diagnosis list.

A52840: Clinical Trials – Medical Policy Article

Article, effective 2026-04-01 · Wellpoint Federal (06101, 06102, 06201, 06202, 06301, 06302, 13101, 13102, 13201, 13202, 13282, 13292, 14111, 14112, 14211, 14212, 14311, 14312, 14411, 14412, 14511, 14512) · CMS record

No covered diagnosis list.

A53784: Billing and Coding: The Routine Costs of Investigational Chemotherapy Drugs Studied In a Qualifying Clinical Trial

Billing and Coding, effective 2020-08-20 · Palmetto GBA (10111, 10211, 10311, 11201, 11301, 11401, 11501) · CMS record

No covered diagnosis list, 1 non-covered.

Coverage analysis history

CMS opens a national coverage analysis (NCA) to create or reconsider an NCD; the analysis carries a CAG tracking number, the evidence review and the decision memo. The Medicare Coverage Database links 2 analyses to NCD 310.1, listed here in the order CMS opened them (by NCA record number). A reconsideration ("Recon") revisits an earlier decision; an analysis whose status is open is still in progress.

  1. CAG-00071R Clinical Trial Policy (1st Recon, Closed)
  2. CAG-00071R2 Clinical Trial Policy (2nd Recon, Closed)

Revision history

04/2024 - The purpose of this Change Request (CR) is to announce a technical change that was made to the National Coverage Determination (NCD) Manual, Publication 100-03, Chapter 1, Part 4, section 310.1 Effective Date 05/27/2024 Implementation Date 05/27/2024 ( TN 12590 ) (CR13597)

09/2007 - Effective Date: 07/09/2007. Implementation Date: 10/09/2007. ( TN 74 ) (CR5719)

09/2000 - Implemented new policy covering routine costs in clinical trials. Effective and implementation dates 09/19/2000. ( TN 126 ) (CR 1241)

How this NCD shows up on remittances

A service denied under a National Coverage Determination returns CARC 50 (not deemed medically necessary) with remark N386 (decision based on an NCD); a denial citing a local policy instead carries N115. Because NCDs bind nationally, the appeal path is documentation that the patient meets the indications above, not a contractor-policy argument.

For teams evaluating QuickIntell software

Evaluate a coverage-review workflow around NCD 310.1

Explore QuickAuth for requirement checks, documentation preparation and status tracking with staff oversight. Bring the policy-review steps your team repeats to a scoped evaluation, and confirm plan-specific requirements and supported actions. Use QuickRCM to evaluate the separate claim and denial workflow; a published NCD is not an authorization or payment guarantee.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — NCD 310.1

What does NCD 310.1 cover?

Effective for items and services furnished on or after July 9, 2007, Medicare covers the routine costs of qualifying clinical trials, as such costs are defined below, as well as reasonable and necessary items and services used to diagnose and treat complications arising from participation in all clinical trials. All other Medicare rules apply. The full indications and limitations are reproduced on this page from the CMS Medicare Coverage Database.

When did NCD 310.1 take effect?

The current version (3) is effective 05/27/2024, implemented 05/27/2024, published in transmittal 12590. CMS lists 3 versions of this NCD.

Does a Local Coverage Determination override NCD 310.1?

No. A National Coverage Determination binds all Medicare Administrative Contractors; an LCD can only address services or circumstances the NCD leaves open. Claims denied under this NCD typically return CARC 50 with remark N386 (NCD) rather than N115 (LCD).

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page reproduces the CMS National Coverage Determination text and, for laboratory NCDs, the CMS ICD-10 edit lists, as an operational reference. Coverage decisions depend on the full policy, the claim and the contractor; nothing here is legal, clinical or billing advice. CPT codes are shown as numbers only; CPT descriptors are copyright AMA.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.